Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity
The OBA SAB will guide the company to develop BIO101 (20-hydroxyecdysone) in obesity, in combination with GLP1-RA, and will actively work towards the finalization of the OBA Phase 2 clinical study design.
- The OBA SAB will guide the company to develop BIO101 (20-hydroxyecdysone) in obesity, in combination with GLP1-RA, and will actively work towards the finalization of the OBA Phase 2 clinical study design.
- Biophytis plans to file for an Investigational New Drug (IND) application to start the OBA Phase 2 clinical study in the USA with FDA in the coming weeks.
- Stanislas Veillet, CEO de Biophytis states: “We are pleased to announce the appointment of Professor Dennis Villareal and Professor Francisco Guarner to the Scientific Advisory Board of the OBA Phase 2 study.
- We are preparing with the SAB to file for an IND to start the OBA phase 2 clinical study in the coming weeks.”
The first two members of Biophytis’ new Scientific Advisory Board for the OBA clinical study are:
at Baylor College of Medicine, Houston, Texas, United States.